Please enable Javascript
ESMO 2023: Focus on Bladder Cancer
Biomarkers of TRAEs in Patients With Advanced UC Treated With EV: Analysis of the UNITE Study
Amanda Nizam, MD
Advanced Urothelial Carcinoma
|
November 20, 2023
Dr. Nizam provides an overview of her recent research on biomarkers of TRAEs associated with EV for aUC.
View More
ESMO Congress Round-Up With Dr. Evan Yu: EV-302 and CheckMate 901
Evan Yu, MD
Advanced Urothelial Carcinoma
|
November 2, 2023
Dr. Evan Yu opines on whether the EV-302 and CheckMate 901 data are practice-changing and when to recommend each combo.
View More
EV-103 Cohort L: Investigating Enfortumab Vedotin as SOC for Cisplatin-Ineligible MIBC
Emily Menendez
ESMO 2023
|
October 30, 2023
Enfortumab vedotin shows promising activity and tolerability in cisplatin-ineligible patients with MIBC.
Read More
Phase 3 THOR Study: Erdafitinib Provides OS Benefit Over Chemotherapy
Emily Menendez
Advanced Urothelial Carcinoma
|
October 27, 2023
Erdafitinib was found to significantly improve OS and boost benefit over chemotherapy in patients with FGFRalt advanced/mUC.
Read More
SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk NMIBC
Zachary Bessette
ESMO 2023
|
October 27, 2023
Results of the phase 2b SunRISe-1 trial showed TAR-200 yields complete responses in BCG-unresponsive high-risk NMIBC.
Read More
Urothelial Carcinoma at ESMO: THOR, DAD, and Other Trials of Note
Brad McGregor, MD
ESMO 2023
|
October 25, 2023
Drs. McGregor, Sonpavde highlight the Double Antibody Drug conjugate trial, updates from THOR, and other studies.
View More
EV-302 and CheckMate 901: Comparing the Practice-Changing ESMO Data for Metastatic UC
Brad McGregor, MD
ESMO 2023
|
October 25, 2023
Drs. McGregor, Sonpavde share how the data compare across CheckMate 901 and EV-302, as well as considerations for physicians.
View More
ICRA Trial Finds Synergy Between Paclitaxel, Tremelimumab for mUC
Emily Menendez
ESMO 2023
|
October 24, 2023
Paclitaxel administered with tremelimumab provided encouraging antitumor activity with a manageable safety profile.
Read More
Novel Erdafitinib Delivery System Safe, Well-Tolerated for NMIBC
Emily Menendez
ESMO 2023
|
October 24, 2023
The TAR-210 delivery system provides a continuous release of erdafitinib to the bladder while limiting systemic toxicities.
Read More
New Standard of Care: EV/Pembro Significantly Improves Survival in Previously Untreated la/mUC
Zachary Bessette
ESMO 2023
|
October 23, 2023
The practice-changing results were presented at ESMO 2023.
Read More
CheckMate 901: Nivolumab Plus Gemcitabine-Cisplatin for Untreated mUC
Zachary Bessette
ESMO 2023
|
October 23, 2023
Nivolumab plus gemcitabine-cisplatin demonstrated meaningful improvements in OS and PFS as first-line treatment of mUC.
Read More
THOR-2 Cohort 1: Recurrence-Free Survival in FGFR-Altered NMIBC After Erdafitinib, Prior BCG
Zachary Bessette
ESMO 2023
|
October 23, 2023
An LBA shed light on the effects of erdafitinib in patients with high-risk NMIBC with select FGFR alterations after BCG.
Read More
Phase 1 DAD Trial: Sacituzumab Govitecan Plus Enfortumab Vedotin Safe, Feasible for mUC
Emily Menendez
ESMO 2023
|
October 18, 2023
The combination of sacituzumab govitecan plus enfortumab vedotin was found to be safe, and provides a high ORR.
Read More
PET-MUSE Study Shows Trend Toward Management Change of Patients With MIBC Undergoing PET
Emily Menendez
ESMO 2023
|
October 18, 2023
PET patients were more likely to have a change in treatment compared with receiving CT alone.
Read More
Erdafitinib Benefits PFS, ORR in Patients With mUC Naïve to Anti-PD-L1
Emily Menendez
ESMO 2023
|
October 18, 2023
Erdafitinib and pembrolizumab had similar OS rates, and toxicities were manageable with dose modifications.
Read More
Advertisement
Advertisement